drugset / Trial / NCT04810507

MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus

NCT04810507

Phase 4 Completed 89 enrolled JW Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

An exploratory study to evaluate the Effect of Improving Glycemic Variability of Anagliptin Compared with Sitagliptin in Patients with Type 2 Diabetes Mellitus

Timeline

Start
2018-11-09
Primary completion
2020-09-02
Completion
2021-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Anagliptin Small molecule 100 mg
Subject Sitagliptin Small molecule 100 mg